Vertex Pharmaceuticals Incorporated
VRTX
$462.13
$5.261.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 6.20B | 6.12B | 6.52B | 5.80B | 10.17B |
| Total Receivables | 1.81B | 1.61B | 1.75B | 1.66B | 1.79B |
| Inventory | 1.36B | 1.21B | 1.08B | 914.60M | 813.10M |
| Prepaid Expenses | 581.60M | 459.20M | 438.70M | 528.50M | 473.40M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 61.20M | 206.50M | 10.50M | 46.90M | 37.70M |
| Total Current Assets | 10.01B | 9.60B | 9.80B | 8.94B | 13.29B |
|
|
|||||
| Total Current Assets | 10.01B | 9.60B | 9.80B | 8.94B | 13.29B |
| Net Property, Plant & Equipment | 2.63B | 2.58B | 2.51B | 1.77B | 1.49B |
| Long-term Investments | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B |
| Goodwill | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B |
| Total Other Intangibles | 441.20M | 825.90M | 831.60M | 837.50M | 834.90M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 3.49B | 3.27B | 3.23B | 3.02B | 2.76B |
| Total Assets | 22.88B | 22.53B | 22.24B | 20.13B | 23.92B |
|
|
|||||
| Total Accounts Payable | 445.00M | 413.00M | 395.80M | 327.90M | 351.40M |
| Total Accrued Expenses | 2.95B | 2.63B | 3.22B | 2.94B | 2.80B |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | 92.30M | 71.20M | -- | -- |
| Total Finance Division Other Current Liabilities | 386.40M | 431.80M | 286.40M | 279.30M | 648.60M |
| Total Other Current Liabilities | 386.40M | 431.80M | 286.40M | 279.30M | 648.60M |
| Total Current Liabilities | 3.78B | 3.56B | 3.97B | 3.55B | 3.80B |
|
|
|||||
| Total Current Liabilities | 3.78B | 3.56B | 3.97B | 3.55B | 3.80B |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 1.65B | 1.66B | 1.70B | 933.40M | 721.30M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 951.90M | 901.80M | 933.30M | 876.80M | 853.60M |
| Total Liabilities | 6.38B | 6.12B | 6.61B | 5.36B | 5.37B |
|
|
|||||
| Common Stock & APIC | 6.18B | 6.68B | 6.91B | 7.10B | 7.29B |
| Retained Earnings | 10.25B | 9.61B | 8.69B | 7.65B | 11.24B |
| Treasury Stock & Other | 68.10M | 127.80M | 28.80M | 22.50M | 17.30M |
| Total Common Equity | 16.50B | 16.41B | 15.63B | 14.77B | 18.55B |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 16.50B | 16.41B | 15.63B | 14.77B | 18.55B |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 16.50B | 16.41B | 15.63B | 14.77B | 18.55B |
|
|
|||||